Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gettinger, S.; Chow, L. Q.; Borghaei, H.; Shen, Y.; Harbison, C.; Chen, A. C.; Rizvi, N. A.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Balmanoukian, A. S.; Rizvi, N. A.; Garon, E. B.; Patnaik, A.; Gandhi, L.; Leighl, N. B.; Goldman, J. W.; Eder, J. P.; Johnson, E. A.; Blumenschein, G. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Safety and efficacy of first-line nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Gettinger, S.; Goldman, J.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J. R.; Shen, Y.; Harbison, C.; Chen, A. C.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Brahmer, J. R.; Gettinger, S.; Chow, L. Q.; Juergens, R.; Shepherd, F. A.; Laurie, S. A.; Gerber, D. E.; Goldman, J.; Shen, Y.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (Anti-PD-1; Bms-936558, Ono-4538) in patients with advanced non-small cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis
    Meeting Abstract

    Rizvi, N. A.; Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; Sequist, L. V.; more...
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
    Meeting Abstract

    Gandhi, L.; Lubiniecki, G.; Balmanoukian, A.; Hui, R.; Hamid, O.; Rizvi, N. A.; Leighl, N.; Gubens, M.; Goldman, J. W.; Emancipator, K.; more...
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab in patients with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis
    Meeting Abstract

    Brahmer, J. R.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; Bms-936558, Ono-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Rizvi, N. A.; Chow, L. Q.; Borghaei, H.; Brahmer, J. R.; Juergens, R.; Shepherd, F. A.; Laurie, S. A.; Gerber, D. E.; Goldman, J.; more...
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab and ipilimumab in first-line non-small-cell lung carcinoma (NSCLC): Interim phase I results
    Meeting Abstract

    Antonia, S. J.; Gettinger, S.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Shen, Y.; Harbison, C.; Chen, A. C.; Ready, N. E.; Rizvi, N. A.
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save